Literature DB >> 1616014

Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure.

I A Reid.   

Abstract

The renin-angiotensin system plays an important role in the regulation of arterial blood pressure and in the development of some forms of clinical and experimental hypertension. It is an important blood pressure control system in its own right but also interacts extensively with other blood pressure control systems, including the sympathetic nervous system and the baroreceptor reflexes. Angiotensin (ANG) II exerts several actions on the sympathetic nervous system. These include a central action to increase sympathetic outflow, stimulatory effects on sympathetic ganglia and the adrenal medulla, and actions at sympathetic nerve endings that serve to facilitate sympathetic neurotransmission. ANG II also interacts with baroreceptor reflexes. For example, it acts centrally to modulate the baroreflex control of heart rate, and this accounts for its ability to increase blood pressure without causing a reflex bradycardia. The physiological significance of these actions of ANG II is not fully understood. Most evidence indicates that the actions of ANG to enhance sympathetic activity do not contribute significantly to the pressor response to exogenous ANG II. On the other hand, there is considerable evidence that the actions of endogenous ANG II on the sympathetic nervous system enhance the cardiovascular responses elicited by activation of the sympathetic nervous system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1616014     DOI: 10.1152/ajpendo.1992.262.6.E763

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  106 in total

Review 1.  The global epidemic of obesity: are we becoming more sympathetic?

Authors:  Kevin P Davy
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

2.  Time-dependent changes in autonomic control of splanchnic vascular resistance and heart rate in ANG II-salt hypertension.

Authors:  Marcos T Kuroki; Pilar A Guzman; Gregory D Fink; John W Osborn
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-11-23       Impact factor: 4.733

3.  No association of angiotensin I converting enzyme I/D polymorphism with domain-specific cognitive function in aged men without dementia.

Authors:  Mu-En Liu; Shih-Jen Tsai; Ti Lu; Cheng-Jee Hong; Ming-Chao Chen; Shoa-Lin Lin; Heng-Liang Yeh; Yan-Chiou Ku
Journal:  Neuromolecular Med       Date:  2011-08-11       Impact factor: 3.843

Review 4.  Major Autonomic Neuroregulatory Pathways Underlying Short- and Long-Term Control of Cardiovascular Function.

Authors:  Ibrahim M Salman
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

Review 5.  Cardiorenal syndrome: still not a defined entity.

Authors:  Carlo Longhini; Christian Molino; Fabio Fabbian
Journal:  Clin Exp Nephrol       Date:  2010-02-20       Impact factor: 2.801

Review 6.  Autonomic and inflammatory consequences of posttraumatic stress disorder and the link to cardiovascular disease.

Authors:  Chevelle Brudey; Jeanie Park; Jan Wiaderkiewicz; Ihori Kobayashi; Thomas A Mellman; Paul J Marvar
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-06-10       Impact factor: 3.619

Review 7.  Angiotensin II, sympathetic nerve activity and chronic heart failure.

Authors:  Yutang Wang; Sai-Wang Seto; Jonathan Golledge
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

8.  Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans.

Authors:  Henrik Vase; Thomas G Lauridsen; Jesper N Bech; Erling B Pedersen
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

9.  The cardiorenal syndrome: making the connection.

Authors:  Gautham Viswanathan; Scott Gilbert
Journal:  Int J Nephrol       Date:  2010-10-04

Review 10.  Clinical profile of eprosartan: a different angiotensin II receptor blocker.

Authors:  P J Blankestijn; H Rupp
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.